171 related articles for article (PubMed ID: 23375249)
1. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
Heinemann V; Douillard JY; Ducreux M; Peeters M
Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
3. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
4. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
5. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
Sridharan M; Hubbard JM; Grothey A
Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
[TBL] [Abstract][Full Text] [Related]
8. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
Stintzing S; Stremitzer S; Sebio A; Lenz HJ
Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
[TBL] [Abstract][Full Text] [Related]
10. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
Osera S; Yoshino T
Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
[TBL] [Abstract][Full Text] [Related]
11. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
Rougier P; Mitry E
Gastroenterol Clin Biol; 2009; 33(8-9):672-80. PubMed ID: 19717258
[TBL] [Abstract][Full Text] [Related]
12. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
13. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
16. Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy.
Marino D; Leone F; D'Avanzo F; Ribero D; Capussotti L; Aglietta M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):218-26. PubMed ID: 24985058
[TBL] [Abstract][Full Text] [Related]
17. Role of targeted agents in metastatic colorectal cancer.
Prenen H; Vecchione L; Van Cutsem E
Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
[TBL] [Abstract][Full Text] [Related]
18. New and potential clinical applications of KRAS as a cancer biomarker.
Kriegshäuser G; Auner V; Zeillinger R
Expert Opin Med Diagn; 2010 Sep; 4(5):383-95. PubMed ID: 23496197
[TBL] [Abstract][Full Text] [Related]
19. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
[TBL] [Abstract][Full Text] [Related]
20. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
Davis LE
Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]